Chemistry:Plosaracetam

From HandWiki

Plosaracetam (INN; developmental code names ABBV-552, SDI-118) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of Alzheimer's disease and other cognition disorders.[1][2][3][4] In contrast to earlier SV2A ligands like levetiracetam and brivaracetam, polsaracetam does not have anticonvulsant activity and instead shows pro-cognitive effects.[4] The drug is being developed by UCB Biopharma and AbbVie.[1][2] As of October 2024, it is in phase 2 clinical trials for Alzheimer's disease and phase 1 trials for cognition disorders.[1][2]

See also

  • List of investigational cognition and memory disorder drugs

References

  1. ↑ 1.0 1.1 1.2 "ABBV 552". 28 October 2024. https://adisinsight.springer.com/drugs/800067095. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Plosaracetam with Synapse". 22 February 2025. https://synapse.patsnap.com/drug/061f3c743a654321a9c262f0effedc78. 
  3. ↑ "ABBV-552". 28 February 2023. https://www.alzforum.org/therapeutics/abbv-552. 
  4. ↑ 4.0 4.1 "SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement". Frontiers in Pharmacology 13. 2022. doi:10.3389/fphar.2022.1066447. PMID 36733374. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Plosaracetam&oldid=4583533"